Abstract
Objective
Thrombotic microangiopathies, namely thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, are uncommon microvascular occlusive diseases. Despite the dramatic improvement in the outcome by exogenous plasma supply, either through plasma infusion or through plasma exchange, patients frequently require support in the intensive care unit. In the present study, we evaluated the outcome of a large cohort of patients with severe thrombotic microangiopathies.
Design
A retrospective multicenter study from January 1998 to June 2001.
Setting
Fourteen French university hospital medical intensive care units.
Patients
Sixty three adult patients with severe thrombotic microangiopathies.
Measurements and results
Of the 63 patients, 19 had a clinical presentation of thrombotic thrombocytopenic purpura, 18 had hemolytic uremic syndrome and 26 had combined neurologic and renal failures. Infections were the main etiology associated with thrombotic microangiopathies. The mortality rate was 35%. Of the survivors, all achieved complete remission. Whereas neurologic failure assessed through the Glasgow coma scale was an independent predictor of mortality [HR=0.845 (CI 95%: 0.759–0.940), P=0.002], renal impairment did not appear to be an adverse prognostic factor. The use of plasma exchange was independently associated with survival [HR=0.269 (CI 95%: 0.104–0.691), P=0.006].
Conclusions
Thrombotic microangiopathies with severe organ dysfunctions leading to hospitalization in the intensive care unit are associated with high mortality. Neurologic impairment appears to be the main adverse prognostic factor correlated to mortality, and the study confirms the importance of plasma exchange in the treatment of high-risk patients.
Similar content being viewed by others
References
Tostivint I, Mougenot B, Flahault A, Vigneau C, Costa MA, Haymann JP, Sraer JD, Rondeau E (2002) Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant 17:1228–1234
Rock G, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, Spasoff R (1992) Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group. Transfusion 32:710–714
Torok TJ, Holman RC, Chorba TL (1995) Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968–1991. Am J Hematol 50:84–90
Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM (1999) Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 131:453–462
George JN (2000) How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 96:1223–1229
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397
Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398–403
Lara PN, Jr., Coe TL, Zhou H, Fernando L, Holland PV, Wun T (1999) Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 107:573–579
Rose M, Eldor A (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 83:437–444
Knobl P, Rintelen C, Kornek G, Wiltschke C, Kalhs P, Schwarzinger I, Globits S, Staudinger T, Laczika K, Kyrle P, Frass M (1997) Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients. Intensive Care Med 23:44–50
Gasparovic V, Radonic R, Mejic S, Pisl Z, Radman I (2000) Possibilities and limits of treatment in patients with thrombotic thrombocytopenic purpura. Intensive Care Med 26:1690–1693
Pene F, Vigneau C, Auburtin M, Moreau D, Coste J, Heshmati F, Mira JP (2003) Severe thrombotic microangiopathy: a retrospective multicenter study. In: 99th international conference of the American Thoracic Society, Seattle, WA, USA. Am J Respir Crit Care Med, pp A249 (abstract)
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2:81–84
Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
Sarode R, Gottschall JL, Aster RH, McFarland JG (1997) Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 54:102–107
Patton JF, Manning KR, Case D, Owen J (1994) Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 47:94–99
Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, Ordinas A, Castillo R (1995) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 70:319–323
McCrae KR, Cines DB (1997) Thrombotic microangiopathy during pregnancy. Semin Hematol 34:148–158
Gordon LI, Kwaan HC (1999) Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 25:217–221
Roy V, Rizvi MA, Vesely SK, George JN (2001) Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27:641–646
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930–1936
de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F (2000) Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 26:915–921
Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT (1981) Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 246:1931–1933
Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, Veyradier A, Leblanc T, Alberti C, Azoulay E, Le Gall JR, Schlemmer B (2003) High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82:27–38
Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347: 589–600
Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666
Gerritsen HE, Robles R, Lammle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661
Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584
Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494
Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765–1772
Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM (2002) von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100:778–785
Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ (2000) Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 111:1215–1222
Acknowledgement
We thank Y.-E. Claessens for helpful review of the manuscript
Author information
Authors and Affiliations
Corresponding author
Appendix A: Participating centers
Appendix A: Participating centers
Hôpital Cochin (F. Pène, J.P. Mira, Paris), Hôpital Tenon (C. Vigneau, E. Rondeau, Paris), Hôpital Bichat (M. Auburtin, M. Wolff, Paris), Hôpital Saint-Louis (D. Moreau, B. Schlemmer, Paris), Hôpital Mondor (J.R. Zahar, C. Brun-Buisson, Créteil), Hôpital Avicenne (Y. Cohen, Bobigny), Institut Gustave Roussy (G. Nitenberg, Villejuif), Hôpital Necker (D. Chauveau, Paris), Hôpital Antoine Béclère (F. Brivet, Clamart), Hôpital Louis Mourier (D. Dreyfuss, Colombes), Hôpital Saint-Antoine (B. Guidet, Paris), Hôpital du Kremlin-Bicêtre (J.L. Teboul, Le Kremlin-Bicêtre), Hôpital Raymond Poincaré (D. Annane, Garches), Hôpital Delafontaine (C. Adrie, Saint Denis)
Rights and permissions
About this article
Cite this article
Pene, F., Vigneau, C., Auburtin, M. et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 31, 71–78 (2005). https://doi.org/10.1007/s00134-004-2505-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-004-2505-0